Cargando…

Immunogenicity of SARS-CoV-2 vaccines in patients with cancer

Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use include new technology mRNA vaccines such as BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), and non...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kakkassery, Helen, Carpenter, Esme, Patten, Piers E.M., Irshad, Sheeba
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345889/ https://www.ncbi.nlm.nih.gov/pubmed/35999131 http://dx.doi.org/10.1016/j.molmed.2022.07.006

Ejemplares similares

Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
por: McKenzie, Duncan R., et al.
Publicado: (2022)

Immunogenicity of Covid-19 Vaccination in Subjects with Myelodysplastic Syndromes
por: Vidler, Jennifer, et al.
Publicado: (2021)

BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes
por: Abdul-Jawad, Sultan, et al.
Publicado: (2022)

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer
por: Denault, Elyssa, et al.
Publicado: (2022)

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
por: Addeo, Alfredo, et al.
Publicado: (2021)

Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
por: McKenzie, Duncan R., et al.
Publicado: (2021)

SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
por: Antonopoulou, Tania, et al.
Publicado: (2022)

SARS‐CoV‐2 immunogenicity at the crossroads
por: Karamloo, Fariba, et al.
Publicado: (2020)

Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy
por: Bowes, Cynthia L., et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
por: Li, Tong, et al.
Publicado: (2022)

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine
por: Zeng, Guangting
Publicado: (2022)

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
por: Kandeil, Ahmed, et al.
Publicado: (2021)

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Malard, Florent, et al.
Publicado: (2021)

Evaluation of Immunogenicity of an Inactivated SARS-CoV-2 Vaccine Prototype in vitro
por: Hancharou, Andrei, et al.
Publicado: (2022)

Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency
por: Arroyo-Sánchez, Daniel, et al.
Publicado: (2021)

SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients
por: Memenga, Felix, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
por: Wu, Yufei, et al.
Publicado: (2023)

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study
por: Naranbhai, Vivek, et al.
Publicado: (2022)

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
por: Joyce, M. Gordon, et al.
Publicado: (2021)

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
por: Joyce, M. Gordon, et al.
Publicado: (2021)

Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice
por: Sundaram, Appavu K., et al.
Publicado: (2021)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
por: Alter, Galit, et al.
Publicado: (2021)

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients
por: Rabinowich, Liane, et al.
Publicado: (2021)

Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2
por: Almansour, Iman, et al.
Publicado: (2021)

Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans
por: Klasse, P. J., et al.
Publicado: (2021)

P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma
por: Malard, Florent, et al.
Publicado: (2021)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein
por: Lim, Heeji, et al.
Publicado: (2022)

Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development
por: Pandey, Apoorva, et al.
Publicado: (2022)

Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity
por: Ng, Ho Yu, et al.
Publicado: (2023)

Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine
por: Grandi, Alberto, et al.
Publicado: (2023)

Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine
por: Grandi, Alberto, et al.
Publicado: (2023)

Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer
por: Han, Yuling, et al.
Publicado: (2022)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
por: Tian, Jing-Hui, et al.
Publicado: (2021)

564. SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity
por: Joyce, M G, et al.
Publicado: (2021)

Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
por: Lázaro-Frías, Adrián, et al.
Publicado: (2022)

SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy
por: Lau, David K, et al.
Publicado: (2022)

Immunogenicity of third dose of anti-SARS-CoV-2 vaccine co-administered with influenza vaccine: An open question
por: Stefanizzi, Pasquale, et al.
Publicado: (2022)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
por: Anderson, Evan J., et al.
Publicado: (2020)

An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines
por: Quinlan, Brian D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9rveusckc6pk28tpj22t7kgtff